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In Search of the Philosopher’s Stone of Cardiology*Jose L. Zamorano, MD, PHD, David del Val, MDH umans have always shown an interest in thecomprehension and control of the future.The verb “to predict” could be deﬁned as
“to state or estimate, especially on the basis of knowl-
edge or reasoning, that an action, event, etc., will
happen in the future or will be a consequence of some-
thing.” Throughout history, many civilizations have
developed predictive models, based mainly on obser-
vation, to make their daily tasks easier.
The Maya Empire, a pre-Columbian culture that
inhabited the region of Central America from 2000 BC
until 1546 BC, conducted rigorous astronomy studies.
By observing the patterns of the sun and moon, the
Maya created a precise and accurate calendar used to
mark the seasons and predict astronomical phenom-
ena. Moreover, by observing the patterns of the
planet Venus, they were able to predict the rainy and
dry seasons to plan tasks related to agriculture, which
were developed with great success and mastery.
Medicine and cardiology are not strangers to this
innate human restlessness. Over the last century,
knowledge advancement related to the pathogenesis
of diseases has supported development of new ther-
apeutic targets that have revolutionized the treat-
ment of many diseases. Despite advances, however,
cardiovascular disease (CVD) prevention and risk
factor control remain a challenge.
The ﬁrst steps in the investigation of tools for pre-
dicting development of atherosclerotic cardiovascular
disease (ASCVD) were taken in the 1930s, when Wil-
helm Raab established a direct relationship between
diet and coronary artery disease, as well as the*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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Spain. Both authors have reported that they have no relationships rele-
vant to the contents of this paper to disclose.association between high cholesterol concentrations
and increased cardiovascular mortality (1). In the
1950s, the U.S. Public Health Service launched several
epidemiological studies, led by the Framingham Heart
Study. Subsequently, the term “risk factor” was used
for the ﬁrst time, in accordance with elevated choles-
terol and high blood pressure levels as predictors of
CVD (2).
Over the past few decades, different algorithms and
risk scales have been created to predict the development
of ASCVD. Recently, the American College of Cardiol-
ogy/American Heart Association published new guide-
lines on cardiovascular risk assessment (3) and
treatment of blood cholesterol to reduce that risk (4).
These guidelines recommend a comprehensive as-
sessment of the estimated 10-year risk for an ASCVD
event, as well as recommended use of additional
markers to improve risk assessment in patients for
whom the indication to initiate statin treatment is un-
clear. The pooled cohort equation (PCE) assessment of
risk was developed by using landmark studies
with racially and geographically diverse cohorts; these
studies included ARIC (Atherosclerosis Risk in
Communities) (5), the Cardiovascular Health Study (6),
and the CARDIA (Coronary Artery Risk Development in
Young Adults) study (7), combined with Framingham
data. The PCE includes the variables age, total and high-
density lipoprotein cholesterol levels, systolic blood
pressure (including treated and untreated hyperten-
sion), diabetes mellitus, and smoking status. According
to these guidelines, the PCE shouldbeused topredict 10-
year risk for thedevelopment ofASCVD innon-Hispanic,
white, andAfrican-Americanwomenandmenages40 to
79 years (Class I, Level of Evidence: B) (3,4).
Furthermore, the European Society of Cardiology,
in its 2012 CVD prevention guidelines, recommends
total risk estimation by using multiple risk factors for
asymptomatic adults without evidence of ASCVD
(Class I, Level of Evidence: C) (8). The Fifth Joint
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149European Societies’ Task Force on Cardiovascular
Disease Prevention in Clinical Practice proposes using
the Systematic Coronary Risk Evaluation (SCORE) to
estimate 10-year risk of a ﬁrst fatal atherosclerotic
event (8,9). The PCE and SCORE risk assessment tools
share many factors, such as age, total cholesterol,
systolic blood pressure, and smoking status. Howev-
er, unlike SCORE, PCE also includes diabetes mellitus
and high-density lipoprotein levels as variables for
estimating 10-year ASCVD event risk.
The risk of clinical events associated with subclini-
cal ASCVD is considered a continuous process. In
recent years, multiple studies (10–14) have evaluated
many early subclinical markers of ASCVD, proposed as
robust predictors for development of cardiovascular
events.SEE PAGE 139In this issue of the Journal, Yeboah et al. (15) report
the results of a study designed to evaluate the
predictive accuracy and the improvement in discrim-
ination gained by adding nontraditional cardiovascu-
lar risk markers included in the latest guidelines, such
as coronary artery calcium (CAC) score, ankle–brachial
index (ABI), high-sensitivity C-reactive protein
(hsCRP) levels, and family history (FH) of ASCVD, as
part of the PCE. The authors used data from MESA
(Multi-Ethnic Study of Atherosclerosis), a prospective
population-based cohort study designed to assess the
prevalence and progression of subclinical ASCVD (16).
Of the 6,814 total participants in MESA, 5,185 par-
ticipants not receiving statins, with a mean age of
61.2 years, were included in this new analysis (53.1%
female, 38% white, 12.1% Chinese, 27% black, and
22.9% Hispanic) (15). It is known that the PCE over-
estimates risk in the MESA population. Thus, to avoid
overstating cardiovascular risk because of the contri-
bution of additional risk factors, the authors calibrated
the PCE and used the new PCE for the analysis. After 10
years of follow-up, a total of 320 (6.2%) ASCVD events
were documented; 139 (43.4%) were acute myocardial
infarction, 132 (41.3%) were fatal or nonfatal strokes,
and 49 (15.3%)were recorded as cardiovascular-related
deaths. CAC score, ABI, and FH of ASCVD indepen-
dently predicted occurrence of cardiovascular events.
Interestingly, the CAC score was the only risk marker
shown to improve, albeit modestly, predictive accu-
racy in addition to the rest of the markers of the cali-
brated PCE. Moreover, the authors suggest that CAC
scores may be useful in individuals in whom quanti-
tative ASCVD risk-based treatment decision making
may be uncertain.
In the previous (2010) American College of
Cardiology/American Heart Association guidelinesfor assessing cardiovascular risk in asymptomatic
adults (17), measurement of CAC received a Class IIa
recommendation (Level of Evidence: B) in adults
at intermediate risk (10% to 20% 10-year risk). The
current guidelines (3), however, downgraded CAC
quantiﬁcation (Class IIb, Level of Evidence: B) and
recommended its use only if, after quantitative
risk assessment, a risk-based treatment decision is
uncertain. In contrast, the European Society of Car-
diology guidelines suggest that CAC quantiﬁcation
should be considered for cardiovascular risk assess-
ment in asymptomatic adults at moderate risk (Class
IIa, Level of Evidence: B) (8).
In our opinion, the development of accurate pre-
dictive models for the progression of coronary disease
in subclinical states remains one of the biggest chal-
lenges in cardiology, often considered the “philoso-
pher’s stone” of this ﬁeld. However, is it enough to
estimate the 10-year risk for ASCVD, or should we aim
for the prediction of lifetime cardiovascular risk?
Although current guidelines recommend determining
10-year risk scores, we are convinced that in the future,
cardiology prevention should go one step further.
Renewed efforts should focus on developing tools not
limited to 10-year risk but rather to predicting indi-
vidual lifetime risk from early ages. Prevention is
essential, but sometimes we do not anticipate enough.
CVDs remain a leading cause of death in developed
countries and are an increasing problem in developing
countries (18–20). In addition, they are one of the main
sources of health care spending and one of the prin-
cipal determinants of disability. According to recent
U.S. data, direct and indirect costs associatedwith CVD
are estimated to exceed $312 billion per year. Thus, we
strongly believe that the capacity for accurate and
early identiﬁcation of individuals by using simple
predictivemodels for lifetime high-risk cardiovascular
events will allow us to focus our efforts on developing
speciﬁc prevention programs and creating cost-
effective strategies.
With great effort and dedication, the Maya
civilization achieved accurate knowledge about
the movement of celestial bodies and astronomical
phenomena that allowed them to anticipate and
improve their daily tasks. Thanks to studies such as
the present one from Yeboah et al. (15), cardiologists
might be closer to predicting the development and
progression of ASCVD.
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